Quick Answer
Crinetics Pharmaceuticals, Inc. reported Research And Development Expense of $332.06 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed an increase of +38.3% in Research And Development Expense from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $2.07 million | Q2 2017: $2.08 million | Q3 2017: $2.52 million | Q4 2017: $2.56 million | Q1 2018: $4.72 million | Q2 2018: $5.22 million | Q3 2018: $6.89 million | Q4 2018: $7.65 million | Q1 2019: $7.26 million | Q2 2019: $10.29 million | Q3 2019: $11.82 million | Q4 2019: $12.14 million | Q1 2020: $13.86 million | Q2 2020: $12.61 million | Q3 2020: $13.70 million | Q1 2021: $17.58 million | Q2 2021: $20.49 million | Q3 2021: $21.58 million | Q1 2022: $28.25 million | Q2 2022: $33.00 million | Q3 2022: $31.99 million | Q1 2023: $38.47 million | Q2 2023: $40.64 million | Q3 2023: $43.84 million | Q1 2024: $53.34 million | Q2 2024: $58.34 million | Q3 2024: $61.91 million | Q1 2025: $76.24 million | Q2 2025: $80.30 million | Q3 2025: $90.46 million.
- Over the full 10 years of available data (2016 to 2025), Crinetics Pharmaceuticals, Inc.'s Research And Development Expense has grown by 6,410.9%.
- Historical annual values: Fiscal year 2025: $332.06 million | Fiscal year 2024: $240.16 million | Fiscal year 2023: $168.53 million | Fiscal year 2022: $130.23 million | Fiscal year 2021: $84.26 million | Fiscal year 2020: $57.00 million | Fiscal year 2019: $41.51 million | Fiscal year 2018: $24.48 million | Fiscal year 2017: $9.23 million | Fiscal year 2016: $5.10 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: